8-K: Adial Pharmaceuticals Changes Auditors, Engaging CBIZ CPAs After Marcum LLP Resignation

Adial Pharmaceuticals has replaced its independent auditor, Marcum LLP, with CBIZ CPAs, effective April 28, 2025, following Marcum's resignation.

Summary

• Adial Pharmaceuticals announced a change in its independent registered public accounting firm.
• Marcum LLP resigned as the company's auditor on April 28, 2025.
• CBIZ CPAs was engaged to serve as the new independent auditor, effective immediately, for the year ending December 31, 2025.
• The Audit Committee of the Company's Board of Directors approved the engagement of CBIZ CPAs.
• Marcum's reports on the company's financial statements for 2024 and 2023 included an explanatory paragraph related to substantial doubt about the company's ability to continue as a going concern.
• There were no disagreements between the Company and Marcum on accounting principles, financial statement disclosure, or auditing scope during the two most recent fiscal years and the subsequent interim period.
• The company reported material weaknesses in its internal control over financial reporting in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• Marcum has provided a letter to the SEC agreeing with the statements made by Adial Pharmaceuticals regarding their firm in the Form 8-K.

Sentiment

Score: 3

Explanation: The change in auditors, coupled with the going concern qualification and material weaknesses in internal control, suggests a negative outlook for the company's financial health.

Positives

• The transition to a new auditor appears to be amicable, with Marcum agreeing with the company's statements in the Form 8-K.
• The Audit Committee approved the engagement of CBIZ CPAs.

Negatives

• Marcum's audit reports for 2024 and 2023 included an explanatory paragraph regarding the company's ability to continue as a going concern.
• The company reported material weaknesses in its internal control over financial reporting in its 2024 Annual Report on Form 10-K.

Risks

• The material weaknesses in internal control over financial reporting could lead to errors or irregularities in the company's financial statements.
• The going concern qualification in Marcum's audit reports indicates significant financial challenges for the company.

Future Outlook

The company will be working with CBIZ CPAs for the audit of the fiscal year ending December 31, 2025.

Industry Context

Changes in auditors are not uncommon, but they can sometimes signal underlying issues with a company's financial reporting or internal controls. Investors often scrutinize these changes to understand the reasons behind them and assess any potential risks.

Comparison to Industry Standards

• Auditor changes are a normal part of business, but the circumstances surrounding the change, such as a resignation, can raise concerns.
• The presence of a going concern qualification is a serious matter and places Adial Pharmaceuticals in a riskier category than companies with clean audit opinions.
• Companies like Cassava Sciences Inc. and Ocugen Inc. have faced scrutiny over their auditor relationships and financial reporting, highlighting the importance of transparency and strong internal controls.

Stakeholder Impact

• Shareholders may be concerned about the company's financial stability and the reliability of its financial reporting.
• Employees may be worried about the company's ability to continue operating.
• Creditors may be hesitant to extend credit to the company.

Key Dates

Keywords

auditor, CBIZ CPAs, Marcum LLP, financial reporting, internal control, Adial Pharmaceuticals